Assertio Therapeutics Inc (DEPO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

Assertio Therapeutics Inc (Assertio), formerly Depomed Inc, is a specialty pharmaceutical company that develops and commercializes drugs for the treatment of pain and other diseases of the central nervous system. Its product portfolio comprises drugs for the treatment of postherpetic neuralgia caused by viral infection, herpes zoster, or nerve damage; management of mild to moderate acute pain in adults; migraine attacks in adults of 18 years of age or above; and pain in cancer patients of 18 years of age and older. The company sells its products to wholesale distributors and retail pharmacies. Assertio also licenses Acuform, its proprietary gastroretentive drug delivery technology. Assertio is headquartered in Lake Forest, Illinois, the US.

Assertio Therapeutics Inc (DEPO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

It derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 5
List of Figures 5
Assertio Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Assertio Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Assertio Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Assertio Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Assertio Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Assertio Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Depomed Acquires Rights to Cosyntropin from Slan Medicinal 11
Depomed Acquires Rights of Cebranopadol from Grunenthal 12
Depomed Acquires US Rights to Nucynta Franchise from Janssen Pharma for USD1.05 Billion 14
Depomed Acquires US And Canadian Rights To Cambia From Nautilus Neurosciences For US$53.7 Million 16
Depomed Acquires Lazanda Nasal Spray From Archimedes Pharma 17
Depomed Acquires Zipsor From Xanodyne Pharma 18
Licensing Agreements 20
Collegium Pharma Enters into Licensing Agreement with Depomed 20
Depomed Enters Into Licensing Agreement With Janssen Pharma 21
Equity Offering 22
Depomed Plans to Raise up to USD300 Million in Public Offering of Securities 22
Depomed Files Registration Statement For Public Offering Of Securities For US$100 Million 23
Debt Offering 24
Depomed Raises USD345 million in Public Offering of 2.5% Notes Due 2021 24
Asset Transactions 26
PDL BioPharma Acquires Remaining 50% Stake in Diabetes Royalty Rights and Milestones from Depomed for USD240.5 Million 26
PDL BioPharma Acquires Portfolio of Diabetes Royalty Rights and Milestones from Depomed for USD240.5 Million 27
Assertio Therapeutics Inc - Key Competitors 29
Assertio Therapeutics Inc - Key Employees 30
Assertio Therapeutics Inc - Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 32
Financial Announcements 32
Aug 08, 2018: Depomed announces second-quarter 2018 financial results 32
May 10, 2018: Depomed Announces First-Quarter 2018 Financial Results 34
Feb 27, 2018: Depomed Announces Fourth Quarter and Full Year 2017 Financial Results 35
Nov 07, 2017: Depomed Announces Third Quarter 2017 Financial Results 37
Aug 07, 2017: Depomed Announces Second Quarter 2017 Financial Results 38
May 09, 2017: Depomed Announces First Quarter 2017 Financial Results and Strategic Initiatives Aimed at Driving Sustainable Long-Term Growth and Shareholder Value 39
Feb 21, 2017: Depomed Reports Fourth Quarter and Full Year 2016 Financial Results 40
Corporate Communications 42
Oct 29, 2018: Assertio Therapeutics appoints Daniel A. Peisert as Senior Vice President and Chief Financial Officer; Current CFO Phil B. Donenberg to Retire November 30, 2018 42
Jun 05, 2018: Depomed Appoints Phillip B. Donenberg As Chief Financial Officer 43
Apr 17, 2018: Depomed Named John B. Thomas as Senior Vice President, Investor Relations and Corporate Communications 44
Apr 17, 2018: Depomed Announces Appointment Of John B. Thomas As Senior Vice President, Investor Relations And Corporate Communications 45
Apr 02, 2018: Depomed Announces the Appointment of Stan Bukofzer as Senior Vice President and Chief Medical and Scientific Officer 46
Oct 18, 2017: Depomed Announces Appointment of Santosh J. Vetticaden, M.D., PH.D. as Senior Vice President, Chief Medical and Scientific Officer 47
Apr 25, 2017: Depomed Announces Appointment of Sharon D. Larkin as Senior Vice President, Human Resources and Administration 48
Other Significant Developments 49
Aug 15, 2018: Depomed announces corporate name change to Assertio Therapeutics 49
Appendix 50
Methodology 50
About GlobalData 50
Contact Us 50
Disclaimer 50

List Of Tables


Assertio Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Assertio Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Assertio Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Assertio Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Assertio Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Assertio Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Depomed Acquires Rights to Cosyntropin from Slan Medicinal 11
Depomed Acquires Rights of Cebranopadol from Grunenthal 12
Depomed Acquires US Rights to Nucynta Franchise from Janssen Pharma for USD1.05 Billion 14
Depomed Acquires US And Canadian Rights To Cambia From Nautilus Neurosciences For US$53.7 Million 16
Depomed Acquires Lazanda Nasal Spray From Archimedes Pharma 17
Depomed Acquires Zipsor From Xanodyne Pharma 18
Collegium Pharma Enters into Licensing Agreement with Depomed 20
Depomed Enters Into Licensing Agreement With Janssen Pharma 21
Depomed Plans to Raise up to USD300 Million in Public Offering of Securities 22
Depomed Files Registration Statement For Public Offering Of Securities For US$100 Million 23
Depomed Raises USD345 million in Public Offering of 2.5% Notes Due 2021 24
PDL BioPharma Acquires Remaining 50% Stake in Diabetes Royalty Rights and Milestones from Depomed for USD240.5 Million 26
PDL BioPharma Acquires Portfolio of Diabetes Royalty Rights and Milestones from Depomed for USD240.5 Million 27
Assertio Therapeutics Inc, Key Competitors 29
Assertio Therapeutics Inc, Key Employees 30
Assertio Therapeutics Inc, Subsidiaries 31

List Of Figures


Assertio Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Assertio Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Assertio Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Assertio Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Assertio Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Assertio Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Assertio Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Assertio Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Assertio Therapeutics Inc (DEPO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Assertio Therapeutics Inc (Assertio), formerly Depomed Inc, is a specialty pharmaceutical company that develops and commercializes drugs for the treatment of pain and other diseases of the central nervous system.

USD 250 View Report

Gene Biotherapeutics Inc (CRXM) - Financial and Strategic SWOT Analysis Review

Gene Biotherapeutics Inc (CRXM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled to

USD 125 View Report

BioClin Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

BioClin Therapeutics Inc (BioClin) is a clinical stage biotechnology company developing protein therapeutics for genetic disorders. Its lead product candidate B-701 is a human monoclonal antibody which targets the activity

USD 250 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available